D towards the sham group (A,A1,J). Sumatriptan let staining shows alterations of your SpVC area in NTG-injected mice (B,B1,J) in comparison to the sham group (A,A1,J). 2-Furoylglycine Data Sheet administration considerably reduces NTG harm in mice (C,C1,J). SCFA treatment, in the highest doses Sumatriptan administration substantially reduces NTG damage in mice (C,C1,J). SCFA therapy, at way than SCFAs (E,E1,F,F1,H,H1,I,I1,J), appreciably restores the trigeminal neurons on the SpVC area inside a more effectivethe highest doses (E,E1,F,F1,H,H1,I,I1,J), appreciably restores the trigeminal neurons on the SpVC location inside a extra effective way than SCFAs at at a dose of 10 mg/kg (D,D1 ,G1,J). Data are representative of at least 3 independent experiments. One-way ANOVA a dose of 10 mg/kg (D,D1 ,G1,J). Data are representative vs. least ## p 0.01 vs. NTG; ### p 0.001 vs. NTG. N = ten test. N.D.: Not Detectable; p 0.001 vs. sham; # p 0.05of at NTG;threeindependent experiments. One-way ANOVA mice/group for every approach.. p 0.001 vs. sham; # p 0.05 vs. NTG; ## p 0.01 vs. NTG; ### p 0.001 vs. NTG. test. N.D.: Not Detectable; N = ten mice/group for every method.3.three. The Effects of SCFAs on the Anti-Inflammatory Pathway in NTG-Induced Migraine three.three. The confirm of SCFAs on the Anti-Inflammatory Pathway in NTG-Induced Migraine iNOS To Effects the anti-inflammatory activity of SCFAs, the levels of COX-2 and had been To confirm the anti-inflammatory activity of SCFAs,iNOS antibodies showed basal exquantified inside the cytosolic fraction. COX-2 along with the levels of COX-2 and iNOS were pression inin the cytosolic fraction. COX-2 and iNOS antibodies showed basal expression in quantified the sham groups, which was significantly increased in the NTG group (Figure 3A,B: see the densitometry analyses, Figure 3A1,B1 in the NTG group (Figure 3A,B: see the the sham groups, which was drastically increased for SP; Figure 3C,D: see the densitometry analyses Figure 3C1,D1 for3A1,B1 for SP; FigureSCFAs see the densitometry analyses densitometry analyses, Figure SB). Treatment with 3C,D: of ten mg/kg did not show any significant Primaquine-13CD3 Biological Activity reduction within the iNOS and COX-2 10 mg/kg did not this expression was Figure 3C1,D1 for SB). Treatment with SCFAs of levels, whereas show any considerable reduction in the iNOS and COX-2 levels, whereas this expression was markedly lowered following the therapy with SCFAs at a dose of 30 mg/kg as well as more at a dose of 100 mg/kg (Figure 3A,B: see the densitometry analyses Figure 3A1,B1 for SP; Figure 3C,D: see the densitometry analyses Figure 3C1,D1 for SB).Cells 2021, 10, x FOR PEER REVIEW9 ofCells 2021, 10,markedly decreased following the therapy with SCFAs at a dose of 30 mg/kg and even 9 of much more at a dose of one hundred mg/kg (Figure 3A,B: see the densitometry analyses Figure 3A1,B118 for SP; Figure 3C,D: see the densitometry analyses Figure 3C1,D1 for SB).Figure three. three. SCFAs administration reduces pro-inflammatoryenzymes in NTG-injected mice. Western blot evaluation of iNOS Figure SCFAs administration reduces pro-inflammatory enzymes in NTG-injected mice. Western blot evaluation of iNOS and COX-2 shows an elevated expression inside the NTG groups in comparison to the sham animals (A,A1,B,B1,C,C1,D,D1). and COX-2 shows an enhanced expression in the NTG groups in comparison to the sham animals (A,A1,B,B1,C,C1,D,D1). SCFAs of of 10 mg/kg are notable to decrease the expression of COX-2 and iNOS; SCFAs at the two highest doses considerably and iNOS; SCFAs at the two highest doses drastically SCFAs ten mg/k.